Chardan Capital Markets analyst Gbola Amusa upgraded Axovant Gene Therapies Ltd. (NASDAQ: AXGT) from Neutral to Buy with a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE